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Traditional systems of medicines have been in use for promo‑
tive, preventive, and curative health services since centuries in 
many parts of the world. Being the oldest traditional system of 
medicine in India, Ayurveda caters to about 80% of the popula‑
tion in developing countries as per the estimate of World Health 
Organization (WHO). Despite their wide usage, research in this 
field is lagging behind with regard to their pharmacologic actions, 
safety, and efficacy. Ashes or Bhasmas used in traditional system of 
medicine contain heavy metal particles in varying proportions. It is 
not easy to write off the usage of these preparations just by presum‑
ing that heavy metals are toxic. Proper scientific documentation 
is required to validate the risks and benefits associated with use 
of such metallic Ayurvedic preparations. There are some specific 
methods for their detoxification and Bhasma preparation, making 
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ABSTRACT
Ash of silver is used in traditional systems of medicine for various neurological conditions like insomnias, neuralgias, anxiety 
disorders, and convulsions. The present study was conducted to evaluate the sedative‑hypnotic activity of ash of silver in comparison 
to pentobarbitone (standard drug) in albino mice. The mice were divided into four groups as follows: Group 1 (control): Gum acacia 
[GA; 1% per os (p.o.)], group 2 (standard): Pentobarbitone [50 mg/kg intraperitoneal (i.p.)], group 3 (test): Ash of silver (50 mg/kg p.o.), 
and group 4: Ash of silver (50 mg/kg p.o.) given 30 min prior to administration of pentobarbitone (50 mg/kg i.p.). Time of onset, 
recovery, and total duration of loss of righting reflex were studied. Ash of silver (test) produced significant sedation (P < 0.01) compared 
to control (GA 1%), but the effect was significantly less compared to that of standard pentobarbitone at the doses used. Also, significant 
potentiation (P < 0.001) of the sedative‑hypnotic effect of pentobarbitone was observed with the test drug.
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them suitable for clinical use in therapeutic doses, as claimed by 
Rasa Shastra experts. There is a need to ascertain whether the 
conventional Shodhan (purification) process of Ayurveda is being 
properly followed or not.[1‑3]
Silver is one among the heavy metals which is considered to 
be a non‑essential accumulative trace element with wide distribu‑
tion in the body, including the central nervous system, but with 
no known biological and physiological function.[4‑6] In Ayurveda, 
preparations like Raupya Bhasma and Kusta Nukras have been 
used to treat many clinical conditions such as pain, inflammation, 
insomnia, neuralgias, anxiety disorders, convulsions, memory loss, 
heat stroke, infections, pro‑myelocytic leukemias, sexual disorders, 
etc., for many centuries. Apart from herbs/shrubs, ashes of silver 
are prescribed. This system also advocates the use of elemental 
or metallic preparations.[7‑9] Metal Bhasmas of gold (e.g., gold 
disodium thiomalate and auranofin) and silver (Raupya Bhasma, 
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Kusta Nukras, etc.) have been used for the treatment of rheumatoid 
arthritis, acute pro‑myelo cytic leukemias, immunostimulation, 
and as analgesics in painful inflammatory conditions, and are 
prescribed with accompaniments such as ginger or cumin water, 
tulsi extract, lemon extract, etc., that have been shown to protect 
against unwanted toxicity due to various reasons which include 
high proportions of trace elements and have synergistic or protec‑
tive effects due to buffering between various constituents or free 
radical scavenging property. Oxides of heavy metals are usually 
not toxic, as claimed by Rasa Shastra.[2,10,11]
Since the safety of ash of silver has already been established, 
reverse pharmacological studies are required to confirm the es‑
tablished facts regarding usage, safety, and efficacy in various 
clinical conditions mentioned above. Since raw silver ore is con‑
sidered hazardous for health as mentioned in Ayurvedic literature, 
it needs to be converted into non‑harmful form (ash of silver) by 
the process of trituration, pulverization, and repeated calcinations 
(at 300°C) for 14 times. Reduced form of silver thus obtained 
acquires spherical nanostructure with a size of 16 nm without any 
change in the morphology of silver, and is now called as ash of 
silver.[4,7,9] Nanosize of the silver particle is probably responsible 
for improving the penetration of silver in brain; hence, ash of silver 
had been used in the past for treatment of various neurological 
conditions, viz. insomnias, anxiety, and pain.[9,10] Being a heavy 
metal preparation, ash of silver bears cumulative potential after 
prolonged use and in overdoses, as seen in preliminary animal 
studies. After certain controversial reports of toxicity due to use 
of metallic/elemental drugs, it has now been made mandatory 
(WHO guidelines) that Ayurvedic drugs in any form should be 
tested for their heavy metal content prior to export, so that heavy 
metals remain within permissible limits.[11‑13]
This study was conducted with an aim (a) to explore the seda‑
tive‑hypnotic effect of ash of silver, if any, as claimed in Ayurvedic 
literature. Further, if ash of silver showed sedative‑hypnotic effect, 
the study aimed (b) to observe whether the test drug ash of silver 
was potentiating the sedative‑hypnotic effect of pentobarbitone at 
the doses used in mice when given 30 min prior to the standard drug.
MATERIALS AND METHODS
Swiss albino mice of either sex weighing between 20 and 30 g 
were screened for the study, after obtaining approval from the In‑
stitutional Animal Ethics Committee. Mice were fed on a standard 
pellet diet and water ad libitum, and were housed in polypropylene 
cages under similar environmental conditions in an animal room 
that was maintained at 24 ± 1°C and 55 ± 5% humidity with a 
12 h light–dark cycle throughout the experiment. In case of oral 
administration, mice were fasted for 12 h before testing. Plexiglass 
chamber was used to observe the responses of mice.
Drugs and dosage forms
The test drug ash of silver was procured from M/s Baidyanath 
Ayurved Bhawan Ltd (Jhansi, India). Ash of silver [50 mg/kg per 
os (p.o.)] was suspended in 1% solution of gum acacia. Gum aca‑
cia (1% p.o.), procured from Arora Pharmacy (New Delhi, India), was 
labeled as cont rol and was administered in a volume of 1 ml/100 g. 
Ash of silver and gum acacia were administered orally using infant 
feeding pipe with a 1 ml syringe attached at the other end. Standard 
sedative‑hypnotic pentobarbitone [50 mg/kg intraperitoneal (i.p.)] 
was procured from Nembutal Dainippon Pharmaceutical Co. (Osaka, 
Japan) and was administered as i.p. injection using 1 ml syringe.
Animals and their grouping
Animals (mice) were divided into four groups consisting of 
six animals in each. Study protocol was as follows:
Group 1:  Received vehicle gum acacia (1% p.o.) as control, given 
in a volume of 1 ml/100 g p.o.
Group 2:  Received pentobarbitone (50 mg/kg i.p.) as the standard 
drug
Group 3:  Received the test drug ash of silver (50 mg/kg p.o.) 
suspended in 1% solution of gum acacia
Group 4:  Received the test drug ash of silver (50 mg/kg p.o.) 
suspended in 1% solution of gum acacia, following 
which the standard drug pentobarbitone (50 mg/kg i.p.) 
was given after 30 min
The responses of all drugs [in terms of time of onset, time 
of recovery, and total duration of loss of righting reflex (LORR) 
in mice] were assessed by continuous observation of animals 
throughout the experiments from the time of administration of 
drug in the plexiglass chamber, using a stop watch.
Measurement of the duration of pentobarbital‑induced 
LORR
The duration of LORR was measured according to the pro‑
cedures described by Marley et al.[14] Mice were given an i.p. 
injection of pentobarbitone (50 mg/kg). When the mice became 
ataxic, they were placed on their backs on a pre‑warmed (37°C) pad 
and  the onset, recovery, and total duration of LORR [starting at the 
time of administration of the test drug (ash of silver), the standard 
drug pentobarbitone (50 mg/kg), and the test drug (ash of silver) 
followed 30 min later by the standard drug pentobarbitone 
(50 mg/kg)] were noted until they regained their righting reflexes. 
Mice were presumed to have regained the righting response when 
they could right themselves three times within 30 sec.
RESULTS
Findings of the present study are depicted in Table 1.
All values were expressed as Mean ± SEM and analyzed using 
analysis of variance (ANOVA)  followed by Dunnett’s “t” test. 
P < 0.05 was considered significant.
DISCUSSION
In the present study, we tried to explore the pharmacological 
effect of ash of silver as a sedative‑hypnotic and its secondary ef‑
fect to potentiate the sedative‑hypnotic effect of pentobarbitone. 
Such studies help to fast track drug discovery and development 
when carried out in selected animal models through screening. 
Thus, Ayurvedic knowledge and experimental database are able 
to provide new functional leads, thereby reducing the toxicity of 
drugs and saving time and money.[13]
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In the present study, ash of silver was observed to possess 
sedative effect at a dose of 50 mg/kg (p.o.) in mice. The seda‑
tive effect was significant (P < 0.01) when compared with the 
vehicle gum acacia (1% p.o.) in mice. The sedative effect of the 
test drug ash of silver was significantly less (P < 0.01) compared 
to pentobarbitone (50 mg/kg i.p.), the standard drug (P < 0.001). 
Significant potentiation (P < 0.001) of the sedative‑hypnotic ef‑
fect of pentobarbitone (50 mg/kg i.p.) was observed with 30 min 
prior administration of the test drug ash of silver (50 mg/kg p.o.).
  The above findings reveal that ash of silver had sedative effect 
at the doses used; therefore, it can  be proposed that ash of silver 
might be acting as a sedative‑hypnotic owing to its pharmaco‑
logical effects probably mediated by inhibition of neuropeptide 
S (NPS) or N‑methyl‑d‑aspartate (NMDA)/histamine/5‑HT3/
dopamine or potentiation of effects mediated through gamma‑ami‑
nobutyric acid (GABA)/glycine or benzodiazepines (BZDs)/opioid 
receptors. NPS was recently identified as the endogenous ligand of 
an orphan receptor, now referred to as the NPS receptor. In vivo, 
NPS produces a unique behavioral profile by increasing wakeful‑
ness and exerting anxiolytic‑like effects.[15‑19]
To explore the mechanism of action of ash of silver as a 
sedative, antagonists/blockers need to be administered against the 
above‑mentioned mediators.   In our previous study, we tried to 
explore the analgesic activity of ash of silver, which is probably 
mediated through opioid receptors as it was observed after admin‑
istering naloxone, the opioid antagonist, although the role of other 
mediators cannot be ruled out.[13] One of the studies has proposed 
that ashes of heavy metals used in traditional systems of medicine 
function as a catalyzer by their presence in intestine, plasma, and 
blood, thereby acting as free radical scavengers.[8,9,11] Ash particles 
of heavy metals (gold, silver) in calcined form, being insoluble, 
exist as nanoparticles (16 nm), which are very tiny particles and 
biocompatible, and therefore can cross the blood–brain barrier to 
exert various central actions as claimed in Ayurvedic literature, 
viz. analgesic, anti‑inflammatory, sedative, anti‑anxiety, cognitive, 
neuroleptic, and antiepileptic.[4‑7,11,20] Lankveld et al. and Kim et al. 
have proved the distribution of nanosized silver particles in the 
central nervous system as well as in other tissues, e.g., liver, kidney 
and spleen, and intestine, when administered by the oral route.
As the findings of our study have shown significant po‑
tentiation of sedative‑hypnotic effect of pentobarbitone with 
30 min prior administration of ash of silver at the dose used, it 
can be hypothesized that there is a possibility of ash of silver 
acting as hepatic cytochrome P450 microsomal enzyme inhibi‑
tor. Further, it can be hypothesized that ash of silver increases 
the plasma levels of pentobarbitone by inhibiting its hepatic 
metabolism, so as to potentiate the sedative/anesthetic effect 
of pentobarbitone. Pentobarbitone is mainly metabolized in the 
liver. Further studies are required to confirm and establish this 
fact also by intracerebroventricular injection of ash of silver in 
the brain of mouse/rats.
Till date, hardly any studies have been conducted to explore the 
pharmacological effects of ash of silver on sedation/sleep in hu‑
man body, in spite of its wide use in humans in Ayurvedic practice 
for many centuries. Studies conducted by Nadeem et al. on silver 
preparations showed their interesting anti‑anxiety, anti‑cataleptic, 
and anti‑aggressive effects. No scientific reports are available to 
confirm these claims except for some preliminary experimental 
studies demonstrating slight diminution of discharge frequency in 
frog nerve‑muscle preparation bathed in 3% suspension of ash of 
silver. The anti‑anxiety and anti‑aggressive effects observed by 
Nadeem et al. support the nerve‑soothing properties (nervine tonic) 
of silver preparations.[11]
In one study, there is a mention of phytochelatins (PCs), 
produced from reduced glutathione present in green plants and 
legumes, which tend to chelate the heavy metals from soil. There‑
fore, it can be postulated that in the presence of vegetarian diet, 
a fraction of ash of silver is also liable to get chelated if taken 
with vegetarian food.[21‑23] Also, the same theory can be applied 
to overcome the toxic effects produced by excess dose of ash of 
silver, as mentioned in the study of Inder et al. Pharmacokinetic 
and pharmacodynamic studies need to be carried out to find if there 
is any interaction of ash of silver if taken with vegetarian diet, so 
as to formulate and revise the dose for human use. The role of 
free radical scavengers needs to be established, which can help to 
reduce the adverse effects of  ash of silver. One of the studies has 
shown the interaction of ash of silver with some biomolecules, 
proteins, vitamins, etc., thus affecting various physiological reac‑
tions.[24‑28] From the observations and results of the study with the 
test drug ash of silver, it can be postulated that at the doses used 
in mice (50 mg/kg p.o.), it acts as a mild to moderate sedative and 
owing to this property, it might have potentiated the duration of 
LORR effect of pentobarbitone (50 mg/kg i.p.), i.e., synergistic 
effect. But as both these drugs are metabolized by the liver to a 
greater extent, inhibition of cytochrome P450 enzymes system in 
the liver by ash of silver cannot be ruled out, which is probably 
responsible for inhibiting the hepatic metabolism of pentobarbitone 
resulting in high plasma levels of pentobarbitone, which might 
have potentiated the sedative‑hypnotic effect of pentobarbitone 
at the doses used in mice.
Table 1. Effects of various drug treatments on sleep in mice
Group no. 
(n=6 in each group)
Drug treatment with dose and route 
of administration
Righting reflex in mice (in min) (mean±SEM)
Time of onset of loss 
of righting reflex (O)
Time of 
recovery (R)
Total duration of loss 
of righting reflex (R‑O)
1 Vehicle, gum acacia (1% p.o.) No effect seen No effect seen No effect seen
2 Pentobarbitone sodium (50 mg/kg i.p.) 11.83±0.74** 33.13±0.43** 21.33±0.57**
3 Ash of silver (50 mg/kg p.o.) 29.33±0.99* 40.07±0.68* 10.74±0.52*
4 Ash of silver (50 mg/kg p.o.) + 
pentobarbitone sodium (50 mg/kg i.p.)
9.78±0.48** 37.10±0.57** 27.32±0.61**
**P<0.001(highly significant), *P<0.01(statistically significant)
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CONCLUSION
Ash of silver possesses significant sedative hypnotic potential 
at a dose used in present animal study. Therefore it can serve as a 
better alternative as sleep inducing drug with a better safety profile 
compared to conventional hypnotics. Further studies will provide 
adequate data to support this evidence.
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